

# Journal of Visualized Experiments

## Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides --Manuscript Draft--

<b>Article Type:</b>	Methods Article - JoVE Produced Video
<b>Manuscript Number:</b>	JoVE60672R4
<b>Full Title:</b>	Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
<b>Section/Category:</b>	JoVE Medicine
<b>Keywords:</b>	Medicine, Duchenne muscular dystrophy (DMD), Clinical trial, Muscle Biopsy, First in human trial, Phosphorodiamidate morpholino oligomers (morpholinos or PMOs), Dystrophin, Skeletal muscle, mRNA splicing, RT-PCR, Western blotting, NS-065/NCNP-01, exon 53 s
<b>Corresponding Author:</b>	Yoshitsugu Aoki, Ph.D., M.D. Kokuritsu Seishin Shinkei Center Kodaira, Tokyo JAPAN
<b>Corresponding Author's Institution:</b>	Kokuritsu Seishin Shinkei Center
<b>Corresponding Author E-Mail:</b>	tsugu56@ncnp.go.jp
<b>Order of Authors:</b>	Joel Z. Nordin Yoshitaka Mizobe Harumasa Nakamura Hirofumi Komaki Shin'ichi Takeda Yoshitsugu Aoki
<b>Additional Information:</b>	
<b>Question</b>	<b>Response</b>
Please indicate whether this article will be Standard Access or Open Access.	Open Access (US\$4,200)
Please indicate the <b>city, state/province, and country</b> where this article will be <b>filmed</b> . Please do not use abbreviations.	Kodaira, Tokyo, Japan



# *National Institute of Neuroscience*

National Center of Neurology and Psychiatry

4-1-1 Ogawa-higashi, Kodaira, Tokyo 187-8502 Japan

9th December 2019

Review Editor

Journal of Visualized Experiments

Re: JoVE60672\_R3

“Characterising exon skipping efficiency in DMD patient samples in clinical trials of antisense oligonucleotides”

Dear Dr Nam Nguyen,

Thank you very much for your consideration of our manuscript and request for a revised version. We also greatly appreciate for your valuable comments and suggestions. We addressed and responded to your comments and recommendations. We hope that our responses and revisions to the manuscript satisfactorily address your comments and that the manuscript is now suitable for publication in Journal of Visualized Experiments.

By submitting the manuscript, the authors assert that the materials presented in this manuscript have not been published before in another scientific journal or is being considered for publication elsewhere. The authors declare no competing financial interests. All authors have read and approved all versions of the manuscript, its content, and its submission.

Thank you for your consideration in advance,

Sincerely yours,

A handwritten signature in black ink that reads 'Yoshitsugu Aoki'.

Yoshitsugu Aoki, M.D., PhD.

Director, Department of Molecular Therapy, National Institute of Neuroscience

National Center of Neurology and Psychiatry (NCNP)

4-1-1, Ogawa-higashi, Kodaira, Tokyo 187-8551, Japan

TEL +81-42- 346-1720 / FAX +81-42- 346-1750

tsugu56@ncnp.go.jp

**TITLE:**

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

**AUTHORS AND AFFILIATIONS**

Joel Z. Nordin<sup>1,§</sup>, Yoshitaka Mizobe<sup>1,§</sup>, Harumasa Nakamura<sup>2</sup>, Hirofumi Komaki<sup>3</sup>, Shin'ichi Takeda<sup>1</sup>, Yoshitsugu Aoki<sup>1</sup>

<sup>§</sup>Both authors contributed equally to this work.

<sup>1</sup>Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan

<sup>2</sup>Clinical Research Support Office, Translational Medical Center, National Center of Neurology and Psychiatry, Tokyo, Japan

<sup>3</sup>Department of Child Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan

Corresponding author

Yoshitsugu Aoki

[tsugu56@ncnp.go.jp](mailto:tsugu56@ncnp.go.jp)

**KEYWORDS:**

Medicine, Duchenne muscular dystrophy (DMD), Clinical trial, Muscle Biopsy, First in human trial, Phosphorodiamidate morpholino oligomers (morpholinos or PMOs), Dystrophin, Skeletal muscle, mRNA splicing, RT-PCR, Western blotting, NS-065/NCNP-01, exon 53 skipping.

**ABSTRACT:**

Duchenne muscular dystrophy (DMD) is a degenerative muscle disease that causes progressive loss of muscle mass, leading to premature death. The mutations often cause a distorted reading frame and premature stop codons, resulting in an almost total lack of dystrophin protein. The reading frame can be corrected using antisense oligonucleotides (AONs) that induce exon skipping. The morpholino AON viltolarsen (code name: NS-065/NCNP-01) has been shown to induce exon 53 skipping, restoring the reading frame for patients with exon 52 deletions. We recently administered NS-065/NCNP-01 intravenously to DMD patients in an exploratory investigator-initiated, first-in-human trial of NS-065/NCNP-01. In this methods article, we present the molecular characterization of dystrophin expression using Sanger sequencing, RT-PCR, and western blotting in the clinical trial. The characterization of dystrophin expression was fundamental in the study for showing the efficacy since no functional outcome tests were performed.

**INTRODUCTION:**

Duchenne muscular dystrophy (DMD) is a degenerative muscle disease causing progressive loss of muscle mass, respiratory failure, and cardiomyopathy, and it leads to premature death<sup>1</sup>. The disease is caused by a lack of the large structural muscle protein dystrophin<sup>2</sup>. Mutations in the DMD-gene on the X-chromosome are recessive, and the disease affects 1 in 3500-5000 new-born males<sup>3-5</sup>. The mutations are often large deletions in a hotspot region

between exons 44 and 55 that lead to a distorted reading frame and premature stop codons, causing nonsense-mediated decay and an almost total lack of dystrophin protein<sup>6-8</sup>. The reading frame can be corrected using antisense oligonucleotides (AONs) that induce exon skipping and restore the reading frame, partially restoring dystrophin expression and delaying disease progression<sup>9-11</sup>. The morpholino AON eteplirsen, which was recently approved by the Federal Drug Agency (FDA), induces skipping of exon 51 and can restore the reading frame in patients with exon 52 deletions<sup>12,13</sup>. However, exon 53 skipping restores the reading frame for patients with exon 52 deletions, and it can potentially treat approximately 10% of DMD patients<sup>14</sup>. The morpholino AON drug NS-065/NCNP-01 has been shown to induce exon 53 skipping in human cells, and we recently administered NS-065/NCNP-01 to DMD patients in a phase 1 open-label dose-escalation clinical trial (hereinafter, referred to as “the study”) (registered as UMIN: 000010964 and ClinicalTrials.gov: NCT02081625)<sup>14</sup>. The study showed a dose-dependent increase of exon 53 skipping based on RT-PCR and dystrophin protein levels based on western blotting, and no severe adverse drug events or dropouts were observed<sup>14</sup>.

In all clinical trials, the analysis of the results are of paramount importance. For DMD clinical trials, a debate is still ongoing regarding the best method to show a treatment benefit. Clinical tests such as the 6-minute walk test have certain drawbacks. Molecular characterization of the dystrophin expression can be performed using several methods, such as RT-PCR, qPCR, digital-PCR, western blotting, and immunohistochemistry. However, the extent of protein expression restoration that is required to impart a clinical benefit remains unclear. In this methods article, we describe in detail the RT-PCR and western blotting methods used to determine the exon skipping and protein levels, respectively, in the phase 1 trial of the AON skipping drug NS-065/NCNP-01<sup>14</sup>.

## **PROTOCOL:**

The operational procedure for the investigator-initiated trial has been approved by the NCNP ethical committee (approval ID: A2013-019).

### **1. Preparation of muscle samples**

NOTE: Biceps brachii or quadriceps muscles are often selected as biopsy sites. However, the tibialis anterior was used in the clinical trial.

#### **1.1. Muscle biopsy from patients**

##### **1.1.1. Mark the incision site before skin preparation.**

##### **1.1.2. Prepare saline-dampened gauze for the biopsy specimen. Squeeze the gauze well.**

1.1.3. Inject local anaesthesia into skin and subcutaneous tissue, but not into muscle. Make sure of the depth of the anesthesia by the absence of cutaneous pain.

NOTE: General anaesthesia is generally used in paediatric patients under 15 years of age.

1.1.4. Make an incision from the skin to the subcutaneous tissue. Use small retractors to open the incision and separate the subcutaneous fat.

NOTE: At this step, a portion of the skin can be cut for fibroblast culture.

1.1.5 Make another small incision in the fascia and cut the fascia further. Clamp the edges using mosquito forceps to expose the muscle.

1.1.6 Use a suture to pull up the selected portion of the muscle. Make a small tunnel using Iris scissors and insert mosquito forceps into the tunnel.

1.1.7 Separate the muscle bundle using forceps and cut both ends of the target portion.

NOTE: Muscle biopsy specimens should be around the size of a pencil for adult patients (length 1.0-1.5 cm, diameter 0.8-1.0 cm). The specimen should be around 1 cm in length and 5 mm in diameter in paediatric patients.

1.1.8 Wrap the specimen in saline-dampened gauze and transport the fresh muscle at room temperature (RT) immediately to a facility where the specimen can be prepared for further analysis.

NOTE: The specimens should be transported at 4 °C if the duration of transportation exceeds 1 hour.

## **2. Muscle sample preparation**

2.1. Mix equal volumes of tragacanth gum and water until the gum becomes soft and sticky. Load the mixture into 25 mL syringes. The syringes can be stored in a refrigerator.

2.2. Place approximately 0.5 to 1 cm of tragacanth gum on cork discs. Label the discs on the opposite side.

2.3. Place a container of isopentane in liquid nitrogen until some of the liquid freezes.

2.4. Place the specimen in the tragacanth gum. The longitudinal axis of each muscle should be perpendicular to the cork. Place gum around the bottom of each muscle to help proper placement.

2.5. Using tweezers, place the muscle/cork specimen in cold isopentane prepared in step 2.3 to freeze. Move the specimen constantly for 1 min or until completely frozen, and place on dry ice temporarily.

2.6. Place the specimen in glass vials and store at -80 °C.

## **3. Muscle sectioning**

3.1. Set up the cryostat for sectioning with a working temperature of -25 °C.

3.2. Mount the cork/muscle block and trim until flat sections are achieved.

3.3. Use a section thickness of 10  $\mu\text{m}$  for RT-PCR and western blotting. Use a thickness of 6–8  $\mu\text{m}$  and 10–12  $\mu\text{m}$  for immunohistochemistry or haematoxylin and eosin staining, respectively. Put sliced sections in 2.0 mL tubes and store at -80 °C for RT-PCR and western blotting.

#### 4. RNA extraction and reverse transcription polymerase chain reaction (RT-PCR)

4.1. Extract approximately 10 slices with 10  $\mu\text{m}$  thickness from frozen muscle by a cryostat. Collect the purified total RNA using the purification kit of total RNA according to the manufacturer's instructions.

4.2. Measure the RNA concentration using a spectrophotometer.

4.3. Combine the required reagents for a RT-PCR reaction in PCR tubes according to **Table 1**. See **Table 2** for primer sequences.

NOTE: The forward primer was 44F for patient NS-03 and 46F for patient NS-07. The reverse primer was 54/55R as a default. If non-specific products were evident, 54R was used as an alternative.

4.4. Place the PCR tubes containing the mixture in a thermo-cycler. Run the thermo-cycler according to **Table 3**.

4.5. Store PCR product at 4 °C for short-term storage or -20 °C for long-term storage.

#### 5. Microchip electrophoresis and exon skipping calculation

NOTE: A microchip electrophoresis (MCE) system is often selected to analyze exon skipping efficiency. In this protocol, we describe the steps necessary to analyze the exon skipping efficiency using a MCE system by manufacturer A as well as from manufacturer B, hereafter called system A and B. During the clinical trial, the exon skipping efficiency was analyzed on system A. However, system A is no longer for sale, and we recommend system B to analyze exon skipping efficiency. We have included protocols for both systems (see section 5.1 for system A and 5.2 for system B). See **Table of Materials** for information regarding system A and B. Furthermore, this step can also be performed with normal agarose gel electrophoresis, but the sensitivity markedly decreases.

##### 5.1. Microchip electrophoresis using System A

NOTE: System A has two types of chips. Here, we describe the steps for the DNA chip.

5.1.1. Equilibrate kit reagents (stain buffer, loading buffer, ladder, and gel buffer) to RT, vortex, and spin down.

5.1.2. To prepare gel-stain buffer (GS), add 12.5 µL of stain buffer to 250 µL of gel buffer and vortex for 10 s. Move the solution to a spin filter tube and centrifuge at 2,400 x g for 15 min. Discard the filter.

NOTE: The filtered GS can be stored at 4 °C for 1 month.

5.1.3. If samples are highly concentrated, dilute to approximately 50 ng/µL with TE buffer or DNase-free water.

NOTE: If samples are in a salt concentration  $\geq$  200 mM KCl (or NaCl) and/or 15 mM MgCl<sub>2</sub>, exchange the buffer.

5.1.4. Add 12 µL of GS solution to the gel priming well (highlighted and labelled GS) of the DNA chip and place the chip in the priming station.

NOTE: To avoid air bubbles, insert the pipette tip vertically and to the bottom of the well when dispensing. Dispense slowly to the first stop on the pipette, and do not expel air at the end of the pipetting step.

5.1.5. Select C3 mode and press the **Start** button. After priming is completed, remove the chip.

5.1.6. Visually inspect the microchannels for trapped air bubbles or incomplete priming.

5.1.7. Load the prepared samples and ladder onto the chip as below.

5.1.7.1. Pipette 9 µL of GS solution into the other 3 GS wells.

5.1.7.2. Pipette 5 µL of loading buffer into the L well and each sample well (1-11).

5.1.7.3. Pipette 1 µL of ladder into the L well.

5.1.7.4. Pipette 1 µL of DNA sample into each of the 11 sample wells.

5.1.7.5. Pipette 1 µL of TE or DNase-free water into any unused wells. The kit quick guide shows a figure of the chip layout.

NOTE: Inspect all wells for air bubbles by holding the chip above a lightly colored background. Dislodge any trapped air bubbles at the bottom of a well with a clean pipette tip or by removing and reloading the solution.

5.1.8. Place the chip in the vortex station and press **Mix**. The vortex station automatically stops after 1 min.

5.1.9. Run the chip in the electrophoresis station within 5 min of loading.

5.1.10. Select **New Run** in the software toolbar. On the **New Run** screen, select **DNA** and **DNA 1K** from the **Assay** pull-down list.

5.1.11. Either select a project folder for the run from the **Project** pull-down list or create a new project folder by entering a name in the **Project** field.

5.1.12. Enter a name for the run in the **Run Prefix** field and click **Start Run**.

5.1.13. The instrument beeps when the analysis is complete, and a window opens indicating the end of the run. Select **OK** and remove the chip from the chip platform.

5.1.14. Select **File | Export Data** to export the data. Select the desired options in the **Export** dialogue.

5.1.15. To clean the electrodes, fill a cleaning chip with 800  $\mu$ L of deionized water and place it on the chip platform, close the lid, and leave it closed for 1 min. After 1 min, open the lid, remove the cleaning chip, and allow the electrodes to dry for 1 min.

## **5.2. Microchip electrophoresis using system B**

5.2.1. Open the operating software and enter the sample information. After entering the information, the software calculates the amount of separating buffer and marker solutions automatically.

5.2.2. Prepare the necessary amount of separating buffer calculated by the software. First, prepare 100x nucleic acid gel stain solution by diluting 10,000x solution with the appropriate amount of TE buffer. The 100x solution can be stored at -20 °C.

5.2.3. Mix a suitable amount of 100x nucleic acid gel stain with separation buffer in the specific tube provided by the company to prepare a 1x solution. Vortex the solution.

5.2.4. Prepare the required amount of marker solution in the tube.

5.2.5. Start the probe wash program.

5.2.6. Start the microchip wash program when finished.

5.2.7. Simultaneously, pipette the samples to a PCR multiplate (96-well, clear) and dilute 4 times with deionized water. The minimum volume the machine can handle is 6  $\mu$ L, and the maximum is 30  $\mu$ L. We suggest a total volume of 10  $\mu$ L (2.5  $\mu$ L of sample and 7.5  $\mu$ L of water/TE-buffer).

5.2.8. Cover the plates with adhesive PCR sealing foil sheets and spin-down the samples.

5.2.9. Set the plate, marker solution, and 1x separating buffer in the machine according to the placement shown by the machine. Push the **Start** button.

5.2.10. When the run is finished, export the result data as a .csv file from the software and calculate the exon skipping efficiency using molar concentration as follows:  
Exon skipping efficiency (%) = (Skipped band / (Skipped band + Non-skipped band) X 100

## 6. Complementary DNA (cDNA) sequencing

### 6.1. Agarose gel preparation

6.1.1. Measure 1.5 g of agarose powder and mix the powder with 100 mL of 1x TAE buffer in a microwavable flask (resulting in a 1.5% agarose gel).

6.1.2. Microwave for 1-3 min until the agarose is completely dissolved.

NOTE: Do not overboil the solution, since some of the buffer will evaporate and alter the final agarose percentage of the gel.

6.1.3. Let the agarose solution cool to about 50 °C.

6.1.4. Add 10 µL 10,000x fluorescent nucleic acid dye to the agarose solution.

6.1.5. Pour the agarose into a gel tray with the well comb in place. Leave at RT for 20-30 min until it has completely solidified.

### 6.2. Sequencing

6.2.1. Mix 5 µL of RT-PCR product (from step 4.4) and 1 µL of 6x loading buffer. Load them into the wells of the 1.5% agarose gel.

6.2.2. Run the gel at 135 V for 5 min and 120 V for 20 min.

6.2.3. Visualize the bands using a transilluminator according to the manufacturer's protocol.

6.2.4. Excise bands of interest from the gel and use a gel and PCR cleanup kit to retrieve RT-PCR products.

6.2.5. Measure the concentration using a spectrophotometer.

NOTE: The purified band can be sent for sequencing at a company or sequencing facility if no Sanger sequencing equipment is available in-house.

6.2.6. Prepare the required reagents for a cycle sequencing kit and pipette into a multiplate PCR plate according to **Table 4**. See **Table 2** for primer sequences.

6.2.7. Seal the plate with clear adhesive film.

6.2.8. Vortex the plate for 2 to 3 s. Centrifuge briefly in a swinging bucket centrifuge so that the contents settle to the bottom of the wells (5 to 10 s) at 1,000 x g.

NOTE: Air bubbles may be present in the wells, but they do not adversely affect the reaction.

6.2.9. Place the mixture in a thermo-cycler and run according to **Table 5**.

6.2.10. Purify the sequencing reactions with plates according to the manufacturer's instructions.

6.2.11. Use an DNA analyzer to determine the sequences according to the manufacturer's protocol.

6.2.12. Compare the sequence obtained to the patient's expected sequence.

## **7. Western blotting**

### **7.1. Sample preparation**

7.1.1. Prepare SDS sample buffer (4% SDS, 4 M urea, 10% 2-mercaptoethanol, 10% glycerol, 70 mM Tris-HCl pH 6.4, 0.001% bromophenol blue, and protease inhibitor).

7.1.2. Place around 100 slices of the 10  $\mu$ m muscle sections collected from cryo-sectioning in 150  $\mu$ L of SDS buffer.

7.1.3. Briefly homogenize the protein samples on ice for 30 s using a handy micro homogenizer.

7.1.4. Centrifuge at 16,500  $\times g$  for 15 min, and transfer the supernatant to a fresh tube. Proceed with analysis or store at -80 °C.

### **7.2. SDS-PAGE for protein concentration measurement**

NOTE: A fluorescent gel stain was used to determine the protein concentration.

7.2.1. Determine the normal healthy control sample weight and the concentration using the BCA protein assay kit according to the manufacturer's instructions.

7.2.2. Prepare the samples for gel electrophoresis. Pipette 10  $\mu$ g of total protein of the healthy control and 5  $\mu$ L of the patient samples, 5  $\mu$ L of 4x sample buffer, 2  $\mu$ L of 10x sample reducing agent. Once these have been mixed, add deionized water to a final volume of 20  $\mu$ L in each sample.

7.2.3. Heat samples at 70 °C for 10 min.

7.2.4. Prepare 2,000 mL of 1x SDS running buffer using 50 mL of 40x SDS running buffer. Dilute with 1,950 mL of deionized water.

NOTE: At this point, 1,000 mL of running buffer is enough. The remaining 1,000 mL buffer is used at step 7.3.1.

7.2.5. Mix thoroughly and set aside 800 mL of the 1x SDS running buffer for use in the lower (outer) buffer chamber of the gel box.

7.2.6. Immediately prior to electrophoresis, add 500  $\mu$ L of antioxidant buffer to 200 mL of 1x SDS running buffer to use in the upper (inner) buffer chamber of the gel box.

7.2.7. Prepare for gel electrophoresis by setting up a 3-8% Tris-acetate gel according to the manufacturer's protocol. Load 20  $\mu$ L of each sample onto the gel.

7.2.8. Perform electrophoresis at 150 V for 75 min.

7.2.9. After electrophoresis, place the gel directly into a clean tray containing 50 mL of fluorescent gel stain solution.

7.2.10. Cover the tray, place on a shaker, and agitate without splashing liquid or damaging the gel for 90 min.

7.2.11. Transfer the gel into water before imaging in a fluorescence system at 312 nm illumination with ethidium bromide emission filter to detect fluorescence.

7.2.12. Measure the concentrations of the patient samples based on an analytical curve constructed using the normal control lysate with known concentration.

### 7.3. SDS-PAGE for western blotting

7.3.1. Prepare the gel box according to steps 7.2.4-7.2.6.

7.3.2. Based on the concentration measurement obtained in step 7.2.11, load 100  $\mu$ g per lane of healthy control lysate and 300  $\mu$ g per lane of the patient sample. Electrophorese using the same settings as step 7.2.7.

### 7.4. Protein transfer

7.4.1. Prepare the transfer buffer. Soak a PVDF membrane for 20 s in methanol. Move it to the blotting buffer B until use.

7.4.2. Soak a extra-thick blotting paper in blotting buffer A, B, and C for at least 30 min per buffer.

7.4.3. After electrophoresis, soak the gel in blotting buffer B for 5 min.

7.4.4. Place blotting papers, PVDF membrane, and gel on the semi-dry transfer machine according to the drawing in Figure 1. Roll out air bubbles between the gel and membrane with a roller.

7.4.5. Transfer at 2 mA/cm<sup>2</sup> membrane for 1 h at RT.

NOTE: After transferring, it is recommended to perform a total protein stain similar to Ponceau staining to confirm successful transfer of the large molecular weight proteins.

## 7.5. Blocking and antibody staining

7.5.1. Rinse the membrane twice with PBST (1x PBS with 0.1% Tween 20).

7.5.2. Place the membrane in 1% blocking agent, and rock gently for 1 h at RT to block.

7.5.3. Incubate the membrane with anti-dystrophin antibody in blocking solution (1:125) and anti-spectrin antibody (1:25,000) for 1 h at RT or overnight at 4 °C.

7.5.4. Wash the membrane three times for 10 min each with PBST at RT.

7.5.5. Incubate the membrane with horseradish peroxidase (HRP)-conjugated secondary anti-mouse/rabbit antibody in PBST (1:100) for 40 min at RT.

7.5.6. Wash the membrane again three times for 10 min with PBST at RT.

## 7.6. Detection

7.6.1. Mix detection solutions A and B in a ratio of 1:1. The final volume of detection reagent required is 0.1 mL/cm<sup>2</sup> membrane.

7.6.2. Remove the excess PBST from the washed membrane and place it with the protein side up on a sheet of plastic wrap or other suitable clean surfaces. Add the mixed detection reagent onto the membrane and incubate for 5 minutes at RT.

7.6.3. Remove the excess detection reagent by holding the membrane gently in forceps and touching the edge against a tissue.

7.6.4. Place the blot protein side up on a sample tray. Operate the fluorescent system according to the user documentation. Set machine as follows. Exposure type: Increment, Interval time: 10 s, Sensitivity/Resolution: high.

NOTE: Measured areas were boxed with a blue rectangle (**Figure 4a-b**): BG: background; D: dystrophin 427 kDa, SL: spectrin beta long isoform (274 kDa); SS: short isoform (253 kDa). Dystrophin/spectrin signal ratio was calculated as (D-BG)/[(SL-BG) + (SS-BG)]. The ratio of normal control was set as 100%.

## REPRESENTATIVE RESULTS

To use RT-PCR to detect exon skipping, primers on either side of the exon that will be skipped were designed and evaluated to yield only specific bands (see **Figure 2** for a schematic diagram of exon skipping and primer position). The primers should generate products that

can easily be distinguished by size on a MCE system or normal agarose gel electrophoresis if MCE is not available. **Figure 3a** shows MCE system A gel images of RT-PCR reactions and the sequencing results of the skipped band from patients NS-03 and NS-07 before and after treatment with NS-065/NCNP-01 in the dose-escalation phase 1 trial. NS-03 and NS-07 harbor deletions that span exons 45-52 and 48-52, respectively. NS-03 received 5 mg/kg and NS-07 20 mg/kg of NS-065/NCNP-01 weekly for 12 weeks. As expected before treatment, both patients showed no skipping, and only a non-skipped band could be visualized. After 12 weeks of treatment, a clear skipped lower band was visualised for NS-07. However, it was still difficult to detect any skipped product for patient NS-03. The sequencing results showed a concatenation of exons 47 and 54 for NS-07, as well as exons 44 and 54 for NS-03. According to the sequence, these could theoretically produce a functional but shortened dystrophin isoform. To calculate the skipping percentage shown in **Figure 3b**, the molar concentration for the skipped band was divided by the skipped and un-skipped band. For patient NS-07, the percentage after treatment was 72%, and it was 3.4% for NS-03. Western blot data (in triplicate) from patients NS-03, NS-07, and a healthy control are shown in **Figure 4a**. Expectedly, no dystrophin band was detected before treatment. After treatment a band from patient NS-07 was detected with a lower molecular weight compared to healthy control (wild type dystrophin has a molecular weight of 427 kDa, and NS-07 dystrophin has a molecular weight of 389 kDa). Because of the exon deletion and skipping, the dystrophin isoform from patient NS-07 lacked several exons, and it was expected to have a lower molecular weight. Patient NS-03 showed no detectable levels of dystrophin after treatment. In **Figure 4b**, the amount of dystrophin compared to a healthy control for patient NS-07 is shown. The location where signal intensities were measured for the calculation of dystrophin restoration are indicated with blue squares. The dystrophin spectrin ratio was used to calculate the amount of dystrophin compared to that of the healthy control. To this end, the signal from the dystrophin minus background was divided by the sum of the two spectrin isoforms (long and short) minus background (see step 8.6.5). The ratio for healthy control was set to 100%. The amount of dystrophin compared to the healthy control in patient NS-07 after treatment was 9.1%. However, the percentage could not be calculated for patient NS-03 due to a weak dystrophin band, which similar to those obtained for prior treatment samples for both patients.

#### FIGURE AND TABLE LEGENDS:

**Figure 1: Schematic diagram of the transfer stack for western blot analysis.** Assembly of the western blot transfer stack with blotting paper soaked in blotting buffer A in the bottom followed by blotting paper soaked in blotting buffer B, PVDF membrane, the 3-8% Tris-Acetate Gel and on the top 2 blotting papers soaked in blotting buffer C is shown.

**Figure 2: Schematic drawing of exon skipping of exon 53 in a patient with exon 45-52 deletion in the *DMD* gene.** For example, patient NS-03 in the dose-escalation clinical trial had this deletion. If exon 53 is retained, the mRNA will be out of frame since the exon-exon junction between exon 44 and 53 disrupts the reading frame, causing a stop codon in exon 53. The reading frame is restored when exon 53 is skipped, and a shorter isoform of dystrophin is produced. To detect exon 53-skipping by RT-PCR, primers in exon 44 and 54 are used so that the PCR-product between skipped and un-skipped mRNA can easily be detected. FWD: forward primer, REV: reverse primer, PMO: phosphorodiamidate morpholino oligomer.

**Figure 3: Skipping efficiency for patients NS-03 and NS-07 from tibialis anterior muscle biopsy samples.** a) Gel image generated by electrophoresis system A of RT-PCR samples of untreated and treated samples from patients NS-03 and NS-07. Upper panel shows NS-03 and lower panel NS-07 in triplicate. For NS-03, the un-skipped band is 422 bp, and the skipped band is 212 bp. For NS-07, the bands are 836 bp and 624 bp, respectively. Sequence analysis showed a concatenation of exon 44 and exon 54 for NS-03 and exon 47 to exon 54 for NS-07. b) Skipping efficiency before and after treatment is shown for patients NS-03 and NS-07, calculated from the molar concentration of the two bands provided by system A as  $\text{skipped band} / (\text{skipped band} + \text{un-skipped band}) \times 100$ . The skipping efficiency for NS-03 was very low after treatment; for NS-07, the skipping efficiency was over 70%.

**Figure 4: Protein quantification of Dystrophin isoforms before and after exon skipping therapy.** a) Protein quantification of dystrophin isoforms before and after exon skipping therapy. Western blot of muscle biopsy from tibialis anterior from patients NS-03 and NS-07 before and after treatment and from healthy control in triplicate. Dystrophin can be seen at 427 kDa for the healthy control and at 389 kDa for NS-07 after treatment. No dystrophin could be detected for either patient before treatment, or neither could any be detected after treatment for patient NS-03. The area in the black box is shown in **Figure 4b**. To the left in each blot the marker is shown. b) The amount of dystrophin restored after treatment for patient NS-07. Dystrophin restoration was calculated based on the intensities of the bands for dystrophin, background, and the long and short isoform of spectrin according to the formula:  $(\text{dystrophin} - \text{background}) / (\text{spectrin L} - \text{background}) + (\text{spectrin S} - \text{background})$  where the ratio for healthy control is set to 100%. The intensity of each band was measured inside the blue boxes shown in the figure. The dystrophin restoration for NS-07 was 9.1% after treatment. The dystrophin signal was too weak to measure in the untreated samples. Marker sizes are shown in kilodaltons. Dys: Dystrophin, BG: background, SL: Spectrin long isoform, SS: Spectrin short isoform, My: Myosin type 1. Marker sizes are shown in kilodaltons.

**Table 1. RT-PCR reagents.** The necessary compounds for one reaction of the RT-PCR.

**Table 2. Primer list.** Sequences for the primers used in this study. F: Forward, R: Reverse.

**Table 3. PCR conditioned used.** Show PCR conditions for the RT-PCR reaction.

**Table 4. Reagents necessary for the sequencing reaction.** Use either Forward or Reverse primer in the setup, not both at the same time.

**Table 5. PCR conditions for the Sanger sequencing.**

## DISCUSSIONS

Clinical trials of DMD have produced both successes and failures in the last few years. Both RT-PCR and western blotting are common techniques to assess the skipping efficiency generated by exon-skipping compounds administered to the patients. However, RT-PCR has been reported to over-estimate the skipping efficiency compared to digital PCR<sup>15</sup>. Although this is due to a number of reasons, it is primarily caused by the more efficient amplification of the smaller skipped fragments during PCR cycles. It appears that RT-PCR used in this clinical trial also generated higher skipping efficiencies compared to the protein expression estimated

by western blotting. According to the FDA, this is a more reliable way to quantify dystrophin restoration<sup>12</sup>. Hence, caution should be exercised when interpreting RT-PCR skipping results; however the samples can still be compared. Samples showing higher skipping efficiencies based on RT-PCR results commonly exhibit higher protein expression levels in western blot analyses.

Since all patients in DMD clinical trials do not have the same deletion pattern, it can be difficult to design primers and probes that are adequately specific to perform digital or qPCR on all samples. Hence, RT-PCR is still a good alternative for a first assessment of the skipping efficiency. Before the clinical trial of NS-065/NCNP-01 commenced, it was tedious to assess skipping efficiency for each patient in vitro since either a muscle or skin biopsy was mandatory to generate patient-specific myoblasts. However, we have recently published a novel technique to generate patient-specific MYOD1-converted, urine-derived cells (UDCs) as a novel DMD muscle cell model<sup>16</sup>. Thus, only urine collected from the patient is required to generate the myoblasts, and no invasive procedure is necessary. We believe that this method can be used to screen different AONs in patient-specific cells. Furthermore, different primers and probes can be tested before the patient starts any clinical trial. This can facilitate the use of qPCR or digital PCR for exon skipping measurement in DMD clinical trials in the future.

For performing western blot analysis in this clinical trial, a single antibody against dystrophin was used, and only one healthy control was used as a reference sample. Hence, the specificity of the antibody was not validated appropriately. This, together with the fact that the antibody only recognises the C-terminal domain of dystrophin, is a limitation of the protocol. More healthy controls and antibodies directed against different domains of the dystrophin molecule are advisable in the future.

Here, we summarized the protocols that were used in the recent exploratory investigator-initiated, first-in-human trial of NS-065/NCNP-01. NS-065/NCNP-01 is potentially applicable to 10.1% of patients with DMD.

#### **ACKNOWLEDGEMENTS:**

We are grateful to Dr Takashi Saito, Dr Tetsuya Nagata, Mr Satoshi Masuda, and Dr Eri Takeshita for scientific discussion.


#### **DISCLOSURES:**


None.


#### **REFERENCES:**



- 1 Bushby, K. et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. *Lancet Neurology*. **9** (2), 177-189 (2010).
- 2 Hoffman, E. P., Brown, R. H., Jr. & Kunkel, L. M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. *Cell*. **51** (6), 919-928 (1987).
- 3 Mendell, J. R. et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. *Annals of Neurology*. **71** (3), 304-313 (2012).
- 4 Moat, S. J., Bradley, D. M., Salmon, R., Clarke, A. & Hartley, L. Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK). *European Journal of Human Genetics*. **21** (10), 1049-1053 (2013).

- 5 Greenberg, C. R. et al. Gene studies in newborn males with Duchenne muscular dystrophy detected by neonatal screening. *Lancet*. **2** (8608), 425-427 (1988).
- 6 Forrest, S. M. et al. Further studies of gene deletions that cause Duchenne and Becker muscular dystrophies. *Genomics*. **2** (2), 109-114 (1988).
- 7 Monaco, A. P., Bertelson, C. J., Liechti-Gallati, S., Moser, H. & Kunkel, L. M. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. *Genomics*. **2** (1), 90-95 (1988).
- 8 Flanigan, K. M. et al. Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort. *Human Mutation*. **30** (12), 1657-1666 (2009).
- 9 Aoki, Y. et al. In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse. *Molecular Therapy*. **18** (11), 1995-2005 (2010).
- 10 Lu, Q. L. et al. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. *Nature Medicine*. **9** (8), 1009-1014 (2003).
- 11 Yokota, T. et al. Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. *Annals of Neurology*. **65** (6), 667-676 (2009).
- 12 Kesselheim, A. S. & Avorn, J. Approving a Problematic Muscular Dystrophy Drug: Implications for FDA Policy. *Journal of the American Medical Association*. **316** (22), 2357-2358 (2016).
- 13 Mendell, J. R. et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. *Annals of Neurology*. **74** (5), 637-647 (2013).
- 14 Komaki, H. et al. Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy. *Science Translational Medicine*. **10** (437) (2018).
- 15 Verheul, R. C., van Deutekom, J. C. & Datson, N. A. Digital Droplet PCR for the Absolute Quantification of Exon Skipping Induced by Antisense Oligonucleotides in (Pre-)Clinical Development for Duchenne Muscular Dystrophy. *PLoS One*. **11** (9), e0162467 (2016).
- 16 Takizawa, H. et al. Modelling Duchenne muscular dystrophy in MYOD1-converted urine-derived cells treated with 3-deazaneplanocin A hydrochloride. *Scientific Reports*. **9** (1), 3807 (2019).









Ratio:	0.076	0.106	0.108	1.121	1.035	1.042
Mean:		0.097			1.066	
% Dystrophin:		9.1%			100%	

Table 1: RT-PCR for Qiagen One Step RT-PCR kit		
Solution	Volume/Reaction (μl)	Final concentration
RNase-free water (provided)	Variable	-
5x QIAGEN OneStep RT-PCR Buffer	5.0	1x
dNTP Mix (containing 10 mM of each dNTP)	1.0	400 μM of each dNTP
Forward Primer (10 μM)	1.5	0.6 μM
Reverse Primer (10 μM)	1.5	0.6 μM
QIAGEN OneStep RT-PCR Enzyme Mix	1.0	-
RNase inhibitor (optional)	Variable	5–10 units/reaction
Template RNA	50 ng	
Total	25	

Table 2: Primer sequence	
Primer	Sequence
44F	5'-CCTGAGAATTGGGAACATGC-3'
46F	5'-AACCTGGAAAAGAGCAGCAA-3'
48F	5'-CCAAGAAGGACCATTTGACG-3'
54/55R	5'-TCTCGCTCACTCACCCTTTT-3'
54R	5'-GTGGACTTTTCTGGTATCAT-3'

Table 3: Thermal cycler condition One Step RT-PCR			
1 cycle	Reverse transcription	30 min	50°C
1 cycle	Initial PCR activation step	15 min	95°C
35 cycles	Denaturation	1 min	94°C
	Annealing	1 min	60°C
	Extension	1 min	72°C
1 cycle	Final extension	7 min	72°C
Hold		∞	4°C

Table 4: Reagents for Sequencing	
Solution	Volume/Reaction (µl)
RNase-free water	Variable
BigDye Terminator 3.1 Ready Reaction Mix	3.5
Forward Primer/Reverse Primer (3.2 µM)	2.0
Template RNA	20 ng
Total	20

Table 5: Thermal cycler condition sequencing		
1 cycle	1 min	96°C
25 cycles	10 s	96°C
	5 s	50°C
	4 min	60°C
Hold	∞	4°C

Name of Material/Equipment	Company	Catalog Number	Comments/Description
100 bp DNA Ladder	Takara	3407A	marker solution for MultiNA
1mol/l-Tris-HCl Buffer Solution(pH 7.6)	Nacalai	35436-01	
2-mercaptoethanol	Nacalai	21418-42	
2-Methylbutane (Isopentane)	Sigma-Aldrich	15-2220	
5 mL Round Bottom Polystyrene Test Tube	Falcon	352235	
6× Loading Buffer	Takara	9156	
Agarose ME	Iwai chemical	50013R	
Applied Biosystems 3730 DNA Analyzer	Applied Biosystems	A41046	
BD Matrigel Matrix	BD Biosciences	356234	
BigDye Terminator v3.1 Cycle Sequencing Kit	Applied Biosystems	4337455	
Bovine Serum Albumin solution	Sigma-Aldrich	A8412	
Bromophenol blue	Nacalai	05808-61	
Centri-Sep 96-Well Plates	Applied Biosystems	4367819	
cOmplete Protease Inhibitor Cocktail	Roche	4693116001	
DMEM/F-12	Gibco	11320033	
ECL Prime Blocking Reagent	GE healthcare	RPN418	
ECL Prime Western Blotting Detection Reagent	GE healthcare	RPN2232	
Endo-Porter	GeneTools	2922498000	
Experion Automated Electrophoresis Station	Bio-Rad	7007010	Microchip electrophoresis system A
Experion DNA 1K Analysis Kit for 10 Chips	Bio-Rad	7007107JA	
Experion Priming Station	Bio-Rad	7007030	
Experion Vortex Station II	Bio-Rad	7007043	
Extra Thick Blot Filter Paper	Bio-Rad	1703965	

EzBlot	Atto	AE-1460
GelRed Nucleic Acid Gel Stain	Biotium	41003
glass vial	Iwaki	1880 SV20
Glycerol	Nacalai	17045-65
Histofine Simple Stain MAX PO	Nichirei	424151
Horse Serum	Gibco	16050122
Immobilon-P Transfer Membrane	Millipore	IPVH304F0
ITS Liquid Media Supplement	Sigma-Aldrich	I3146
Methanol	Sigma-Aldrich	34860
	Applied	
MicroAmp Clear Adhesive Film	Biosystems	4306311
MultiNA	SHIMADZU	MCE-202
Multiplate 96-Well PCR Plates	Bio-Rad	mlp9601
NanoDrop One Microvolume UV- Vis Spectrophotometer with Wi-Fi	Thermo Scientific	ND-ONE-W
Novocastra™ Lyophilized Mouse Monoclonal Antibody Dystrophin (C-terminus)	Leica biosystems	NCL-DYS2
Novocastra™ Lyophilized Mouse Monoclonal Antibody Spectrin	Leica biosystems	NCL-SPEC1
NuPAGE 3-8% Tris-Acetate Protein Gels	Invitrogen	EA03785BOX
NuPAGE Antioxidant	Invitrogen	NP0005
NuPAGE LDS Sample Buffer	Invitrogen	NP0007
NuPAGE Sample Reducing Agent	Invitrogen	NP0009
NuPAGE Tris-Acetate SDS Running Buffer	Invitrogen	LA0041
Oriole Fluorescent Gel Stain	Bio-Rad	1610496
PBS	Gibco	10010023

Microchip electrophoresis system B

Penicillin-Streptomycin Solution			
Stabilized	Sigma-Aldrich	P4458	
Physoctron Handy micro-			
homogenizer	MICROTEC	NS-310E3	
Pierce BCA Protein Assay Kit	Thermo Scientific	23227	
Polybrene Infection / Transfection			
Reagent	Sigma-Aldrich	TR-1003	
Propidium Iodide Staining Solution	BD Pharmingen	556463	
QIAGEN OneStep RT-PCR Kit	Qiagen	210212	
RNeasy Fibrous Tissue Mini Kit	Qiagen	74704	
SDS	Nacalai	31606-75	
Semi-dry transfer machine	Bio Craft	41-1293	
SYBR Gold Nucleic Acid Gel Stain	Invitrogen	S11494	for MultiNA
TAE Buffer	Nacalai	35430-61	
Tragacanth Gum	Wako	200-02245	
Tris-EDTA Buffer	Nippon Gene	316-90025	for MultiNA
Trypsin-EDTA (0.05%)	Gibco	25300054	
TWEEN 20	Sigma-Aldrich	P9416	
Urea	Nacalai	35907-15	
Wizard SV Gel and PCR Clean-Up			
System	Promega	A9281	
XCell SureLock Mini-Cell	Invitrogen	EI0001	

OUR RESPONSES TO THE EDITOR'S COMMENTS ARE SHOWN IN **RED**.

Thank you for your letter concerning the mentioned manuscript. We have revised the manuscript according to the editor's comments.

***In Response to Editorial comments:***

**Comment1:** Please review the Figures and the legends. There is disagreement there as there are 4 figure legends but 5 figures attached. Furthermore, please ensure that the legend matches the figure.

**Response 1:** We have reviewed the figures and legends and changed the correct figures.

**Comment 2:** The tables were missing but I uploaded them from the R1 revision. Please review for accuracy.

**Response 2:** Thank you for your effort. We have added the correct tables.

**Comment 3:** Please do not abbreviate journal titles in the references.

**Response 3:** We have changed the references using JoVE EndNote style file.

We would like to thank the editor for your helpful comments and hope that the revised manuscript is acceptable for publication in JoVE.